-

+ AML in April, 2005, characterized as AML-M4 (FAB classification), BM cytogenetics with no clonal anomaly (46,XX[12]), immunophenotyping of blast cells showed positivity for CD34, HLA-DR,CD117, cMPO, CD33, CD13, CD4, CD15, CD64 and CD71. The patient was treated with Idarubicin for 3 days, and Ara-C for 7 days, with complete remission. Consolidation chemotherapy with HDARA-C was done. In September, 2005 a full-matched related bone marrow transplantation was performed, from her brother. Karyotypes performed in April and September, 2006 and September, 2007 showed a complete chimerism (//46,XY[20]).

-

40 yrs

F

-

-

-

-

312

8,7

27

98

90% myeloid/monocytic blast cells

AML-M4

blast cells positivity for: CD34, HLA-DR,CD117, cMPO, CD33, CD13, CD4, CD15, CD64 and CD71.

not done

not done

not done

AML-M4 in first relapse after allogeneic BMT.

01-2008

Idarubicin + ARA-C (I3A7)

-

+

-

D

02-2008

1,5

Bone Marrow

24 and 48- hours without stimulating agents

G- band

46,XX, (5;17)(q13;q21)[20]//

not applied

not done

not done

The present case was the first that described the t(5;17) as a sole cytogenetic anomaly in AML. Unfortunately we could not review the first karyotype to see if there was a small clone with translocation, but the finding of the same phenotype at diagnosis and relapse suggests that this could be a primary event in this leukemia. More than this, this could be a very interesting rearrangement to study, as it was found in T-ALL, BAL and AML.